this invention relates to novel substituted tryptamines and related derivatives , as well as pharmaceutical compositions formulated therefrom . these compounds , compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system . these compounds and conditions can be used for treating several types of medical conditions , such as central nervous system and psychiatric disorders , chronobiological - based disorders , neoplastic conditions , and conditions associated with senescence .